Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Otsuka Pharmaceutical Co: Clinical Trials & FDA Approval Profile

Otsuka Pharmaceutical Co (Global / Institutional) sponsors 28 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 8 active protocols (6 recruiting now), 18 completed protocols, and 1 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)7.1%
Median Closed Enrollment vs National (145 pts)176 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Otsuka Pharmaceutical Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)28
Active Pipeline (Recruiting Now)8 (6)
Completed vs Stopped Early18 / 2 (7.1%)
Median Closed Actual Enrollment176 participants
Physical Hospital Site Disclosure97.1% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals1 (1 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Otsuka Pharmaceutical Co
Hospital Research SiteLocationShared Protocols
Hokkaido University HospitalSapporo, Hokkaido2
Yamagata University HospitalYamagata2

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Otsuka Pharmaceutical across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Otsuka Pharmaceutical Co Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI